We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Parasite Alleles Linked to Severe Illness in Newborns

By LabMedica International staff writers
Posted on 26 Apr 2012
Strains of the Toxoplasma gondii parasite have been identified that are most strongly associated with premature births and severe birth defects.

A new blood test has been developed detect the presence of strain-specific antibodies to pinpoint T. More...
gondii strains that children acquire from their acutely infected mothers while in the womb.

Scientists at the US National Institute of Allergy and Infectious Diseases (NIAID; Bethesda, MD, USA) applied the test to blood samples collected between 1981 and 2009 as part of the National Collaborative Chicago-Based Congenital Toxoplasmosis Study. Sera were obtained from 183 mothers who transmitted T. gondii to their fetuses and 151 infants, most diagnosed with substantial disease as newborns.

Studies performed included the Sabin-Feldman Dye test; immunoglobulin G (IgG) and immunoglobulin M (IgM) enzyme linked immunosorbent assays (ELISA) on maternal serum; IgM immunosorbent agglutination assay on newborn samples; immunoglobulin A (IgA) ELISA on mother and child sera; differential agglutination tests and avidity assays on maternal samples. Presence of strain-specific antibodies in people infected by parasites with type II or non-II alleles was determined in an ELISA using polymorphic peptides derived from two T. gondii dense granule proteins (GRA6 and GRA7) and two control peptides coupled to keyhole limpet hemocyanin (Biosource; Camarillo, CA, USA).

The scientists found evidence of either type II or not exclusively type II strains (NE-II) infections in 183 of the mother-child pairs in the national congenital toxoplasmosis study. The NE-II parasites were more likely to be associated with premature birth, and infants infected with these strains were more likely to have severe manifestations of disease than infants infected by type II parasites. Severe eye damage was seen in 59 out of 88 (67%) of NE-II cases, while such eye damage was present in only 18 out of 46 (39%) of type II cases.

Rima McLeod, MD, from the University of Chicago (IL, USA) and principal author of the study, said, "In the United States, obstetrical screening for Toxoplasma infection is rarely practiced. This new study underscores the value of identifying all patients who will benefit from treatment and suggests that widespread screening and treatment of pregnant women who are infected could prevent infants from suffering eye and brain damage due to congenital toxoplasmosis." The study was published on April 11, 2012, in the journal Clinical Infectious Diseases.

Related Links:

US National Institute of Allergy and Infectious Diseases
Biosource
University of Chicago



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.